Zacks Investment Research lowered shares of Nu Skin Enterprises, Inc. (NYSE:NUS) from a buy rating to a hold rating in a report released on Thursday.
According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “
Several other analysts have also commented on the stock. TheStreet raised shares of Nu Skin Enterprises from a c+ rating to a b rating in a research report on Wednesday, August 2nd. Stifel Nicolaus set a $50.00 price target on shares of Nu Skin Enterprises and gave the company a sell rating in a research report on Thursday, August 3rd. BidaskClub lowered shares of Nu Skin Enterprises from a strong-buy rating to a buy rating in a research report on Monday, July 31st. Bank of America Corporation lifted their price target on shares of Nu Skin Enterprises from $53.00 to $57.00 and gave the company an underperform rating in a research report on Monday, July 10th. Finally, Pivotal Research reaffirmed a buy rating and set a $80.00 price target (up previously from $65.00) on shares of Nu Skin Enterprises in a research report on Thursday, June 22nd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $62.00.
Shares of Nu Skin Enterprises (NYSE:NUS) traded up 1.34% during midday trading on Thursday, reaching $62.74. The company’s stock had a trading volume of 287,524 shares. Nu Skin Enterprises has a 52 week low of $46.35 and a 52 week high of $65.98. The stock has a market capitalization of $3.32 billion, a PE ratio of 20.98 and a beta of 1.40. The company has a 50 day moving average price of $60.95 and a 200-day moving average price of $58.95.
Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings results on Wednesday, August 2nd. The company reported $0.77 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.08. The firm had revenue of $550.10 million for the quarter, compared to analyst estimates of $548.09 million. Nu Skin Enterprises had a net margin of 7.53% and a return on equity of 24.14%. The business’s revenue for the quarter was down 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.79 EPS. On average, equities research analysts expect that Nu Skin Enterprises will post $3.23 EPS for the current year.
WARNING: This article was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://transcriptdaily.com/2017/10/08/nu-skin-enterprises-inc-nus-downgraded-by-zacks-investment-research.html.
The business also recently announced a quarterly dividend, which was paid on Wednesday, September 13th. Investors of record on Friday, August 25th were issued a $0.36 dividend. The ex-dividend date of this dividend was Wednesday, August 23rd. This represents a $1.44 annualized dividend and a yield of 2.30%. Nu Skin Enterprises’s dividend payout ratio (DPR) is presently 48.81%.
In related news, General Counsel D Matthew Dorny sold 7,500 shares of Nu Skin Enterprises stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $60.88, for a total value of $456,600.00. Following the completion of the sale, the general counsel now owns 52,230 shares in the company, valued at approximately $3,179,762.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel W. Campbell sold 4,607 shares of Nu Skin Enterprises stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $62.48, for a total transaction of $287,845.36. Following the completion of the sale, the director now owns 63,753 shares of the company’s stock, valued at approximately $3,983,287.44. The disclosure for this sale can be found here. Insiders sold a total of 20,107 shares of company stock valued at $1,264,445 in the last quarter. 5.20% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Nu Skin Enterprises by 1.8% in the 2nd quarter. BlackRock Inc. now owns 6,805,093 shares of the company’s stock valued at $427,632,000 after purchasing an additional 121,562 shares during the last quarter. Vanguard Group Inc. increased its holdings in Nu Skin Enterprises by 0.8% in the 2nd quarter. Vanguard Group Inc. now owns 6,060,437 shares of the company’s stock valued at $380,838,000 after purchasing an additional 48,805 shares during the last quarter. Wellington Management Group LLP increased its holdings in Nu Skin Enterprises by 7.3% in the 1st quarter. Wellington Management Group LLP now owns 1,944,383 shares of the company’s stock valued at $107,991,000 after purchasing an additional 131,493 shares during the last quarter. State Street Corp increased its holdings in Nu Skin Enterprises by 76.7% in the 1st quarter. State Street Corp now owns 1,416,873 shares of the company’s stock valued at $78,695,000 after purchasing an additional 614,817 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Nu Skin Enterprises by 6.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,067,875 shares of the company’s stock valued at $67,106,000 after purchasing an additional 64,767 shares during the last quarter. Hedge funds and other institutional investors own 79.25% of the company’s stock.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises Inc. and related companies with MarketBeat.com's FREE daily email newsletter.